Physician profile
Jeffrey E Liu
NPI 1750359709
$8,230.73
in general payments reported to CMS, 2019-2025
30 companies · $1,414 in 2025
The $1,414 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2020: $397 · 2021: $1,920 · 2022: $1,944 · 2023: $1,520 · 2024: $848 · 2025: $1,414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,619 · Education: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,618.76 |
| Education | $163.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,423.87 | 2019-2025 | |
| Ucb, INC. | $1,396.93 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Sunovion Pharmaceuticals INC. | $1,221.91 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $984.39 | 2020-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Pfizer INC. | $866.82 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $441.90 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $365.73 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $281.22 | 2021-2025 | Trintellix, Hyqvia |
| Allergan, INC. | $151.80 | 2020 | |
| Upsher-Smith Laboratories LLC | $149.87 | 2020-2022 | |
| Lundbeck LLC | $140.78 | 2019-2025 | Vyepti |
| Acadia Pharmaceuticals INC | $112.94 | 2019-2025 | Nuplazid |
| Idorsia Pharmaceuticals US INC | $77.70 | 2022-2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $75.97 | 2021-2025 | Crexont |
| Novartis Pharmaceuticals Corporation | $61.59 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $61.43 | 2019-2020 | |
| Tanabe Pharma America, INC. | $59.48 | 2021-2022 | |
| Amgen INC. | $42.74 | 2021-2025 | Uplizna |
| Horizon Therapeutics Plc | $40.36 | 2021 | |
| Livanova USA, INC. | $37.91 | 2022-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Argenx US, INC. | $35.88 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Vanda Pharmaceuticals INC. | $32.50 | 2025 | Ponvory |
| Genentech USA, INC. | $27.52 | 2023 | Evrysdi |
| Abbott Laboratories | $24.94 | 2023 | Infinity |
| Alnylam Pharmaceuticals INC. | $22.47 | 2021 | |
| Hologic Sales and Service, LLC | $19.70 | 2025 | Aptima |
| Ge Healthcare | $19.44 | 2022 | |
| Avanir Pharmaceuticals, INC. | $18.54 | 2022 | |
| Kyowa Kirin, INC. | $18.41 | 2023 | Nourianz |
| Neurelis, INC. | $15.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.